Role of NK1.1+ and AsGm-1+ cells in oral immunoregulation of experimental colitis

Inflammatory Bowel Diseases

Volumn 9, Issue 2, 2003, Pages 75-86

  Trop, Shivti ^a   Nagler, Arnon ^a   Ilan, Yaron ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

AsGm 1; Experimental colitis; NK1.1 T cells; Oral tolerance

Indexed keywords

CD4 ANTIGEN; CONCANAVALIN A; CYTOKINE; GAMMA INTERFERON; GANGLIOTETRAOSYLCERAMIDE; INTERLEUKIN 12; INTERLEUKIN 4; PROTEIN ANTIBODY; TRINITROBENZENESULFONIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CELL CULTURE; COLITIS; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; MALE; MOUSE; MOUSE STRAIN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SCORING SYSTEM; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS; ANTIGENS, SURFACE; ASIALOGLYCOPROTEIN RECEPTOR; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; COLITIS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; IMMUNE TOLERANCE; IMMUNOHISTOCHEMISTRY; KILLER CELLS, NATURAL; LECTINS, C-TYPE; MALE; MICE; MICE, INBRED C57BL; PROBABILITY; PROTEINS; RANDOM ALLOCATION; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TH1 CELLS; TRINITROBENZENESULFONIC ACID;

EID: 0347926254     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200303000-00001     Document Type: Review

References (65)

1. Weiner HL. Oral tolerance: immune mechanisms and treatment of autoimmune diseases. Immunol Today 1997;18:335-343.
2. Strobel S, Mowat AM. Immune response to dietary antigens: oral tolerance. Immunol Today 1998;4:173-81.
3. Mizoguchi A, Mizoguchi E, Chiba C, et al. Cytokine imbalance and auto-antibody production in T cell receptor-mutant mice with inflammatory bowel disease. J Exp Med 1996;183:847-56.
4. Strober W, Kelsall B, Fuss L, et al. Reciprocal IFN-γ and TGF-β responses regulate the occurrence of mucosal inflammation. Immunol Today 1997;18:61-4.
5. Neurath M, Kelasall BL, Presky DH, et al. Experimental granulomatous colitis in mice is abrogated by induction of TGFβ-mediated oral tolerance. J Exp Med 1996;183:2605-16.
6. Ilan Y, Weksler-Zangen S, Ben-Horin S, et al. Treatment of experimental colitis by oral tolerance induction: A central role for suppressor lymphocytes. Am J Gastroenterol 2000;95:966-73.
7. Trambley-J, Bingaman-AW, Lin-A, et al. Asialo GM1(+) T cells play a critical role in co-stimulation blockade-resistant allograft rejection. J Clin Invest 1999;104:1715-22.
8. Crispe N, Mehal WZ. Strange brew: T cells in the liver. Immunol Today 1996;11:236-45.
9. Slifka-MK, Pagarigen-RR, Whitton-JL. NK markers are expressed on a high percentage of virus specific CD8+ and CD4+ T cells. J Immunol 2000;164:2009-15.
10. MacDonaland RH. NK1.1+ T cells: New clues to their origin, specificity and function. J Exp Med 1995;182:633-8.
11. Bendelac A. Mouse NK1.1+ T cells. Curr Opin Immunol 1995;7:367-74.
12. Trop S, Samsonov D, Gotsman I, et al. Liver associated lymphocytes expressing NK1.1 are essential for oral tolerance induction in a murine model. Hepatology 1999;27:746-55.
13. Kasai M. et al. In-vivo effect of anti-asialo GMI antibody on natural killer activity. Nature 1981;291:334-5.
14. Lee-U, Santa-K, Habu-S, et al. Murine asialo GM1+CD8 T cells as novel interleukin-12 responsive killer T cell precursors. J Cancer Res 1996;87:429-32.
15. Vicari AP, Zlotnik A. Mouse NK1.1+ T cells: a new family of T cells. Immunol Today 1996;17:71-4.
16. Schultz RJ, Parkes A, Mizoguchu E, et al. Development of CD4- CD8- αβTCR+NK1.1+ lymphocytes. J Immunol 1996;157:4379-89.
17. Bendelac A, Rivera MN, Park SH, et al. Mouse CD1 specific NK1 T cells: development, specificity and function. Annu Rev Immunol 1997;15:535-62.
18. Maruyama S, Tsukahara A, Suzuki S, et al. Quick recovery in the generation of self reactive CD4-low natural killer T cells by an alternative intrathymic pathway when restored from acute thymic atrophy. Clin Exp Immunol 1999;45:587-95.
19. Enomoto A, Nishimura H, Yoshikai Y. Predominant appearance of NK1.1+ T cells producing IL-4 may be involved in the increased susceptibility of mice with the Beige mutation during Salmonella infection. J Immunol 1997;158:2268-77.
20. Brown DR, Fowell DJ, Corry DB, et al. β2-microglobulin-dependent NK1.1+ T cells are not essential for T helper cell immune responses. J Exp Med 1996;184:1295-1304.
21. Arase H, Arase-Fukushi N, Good RA, et al. Lymphokine-activated killer cell activity of CD4-CD8-TCR+ thymocytes. J Immunol 1993;151:546.
22. Chen H, Paul W.E. Cultured NK1.1+CD4+T cells produce large amount of IL4 and IFNγ upon activation by anti-CD3 or CD1. J Immunol 1997;159:2240-9.
23. Ogasawara-K, Takeda-K, Hashimoto-W, Satoh-M, et al. Involvement of NK1+ T cells and their IFN-gamma production in the generalized Shwartzman reaction. J Immunol 1998;160:3522-7.
24. Kawamura T, Takeda K, Mendiratta SK, et al. Critical role of NK1+ T cells in IL-12 induced immune response in-vivo. J Immunol 1998;160:16-9.
25. Wynn AT, Reynolds A, James S, et al. IL-12 enhances vaccine-induced immunity to Schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite. J Immunol 1996;157:4068-78.
26. Godfrey DJ, Hammond KJ, Poulon LD, et al. NKT cells: facts, functions and fallacies. Immunol Today 2000;21:573-83.
27. Abo T, Kawamura T, Wataanabe H. Physiological responses of extrathymic T cells in the liver. Immunol Rev 2000;174:135-49.
28. Samsonov D, Trop S, Alper R, et al. Enhancement of immune tolerance via induction of NK1.1 positive liver-associated-T-lymphocytes under immunosuppressive conditions in a murine model. J Hepatol 2000;32:812-20.
29. Shlomai A, Trop S, Gotsman I, et al. Immunomodulation of experimental colitis: The role of NK1.1+ liver lymphocytes and surrogate antigens - bystander effect. J Pathol 2001;195:498-507.
30. Weiner H, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ- specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol 1998;12:809-37.
31. Ilan Y, Sauter B, Roy Chowdhury N, et al. Oral tolerization to adenoviral proteins permits repeated adenovirus-mediated gene therapy in rats with pre-existing immunity to adenovirus. Hepatology 1998;27:1368-76.
32. Ilan Y, Prakash R, Davidson A, et al. Oral tolerization to adenoviral antigens permits long term gene expression using recombinant adenoviral vectors. J Clin Invest 1997;99:1098-1106.
33. Takahashi M, Ilan Y, Sengupta K, et al. Induction of tolerance to recombinant adenoviruses by injection into newborn rats: Long term amelioration of hyperbilirubinemia in Gunn rats. J Biol Chem 1996;271:26536-42.
34. Ilan Y, Jona VK, Sengupta K, et al. Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses. Hepatology 1997;26:949-56.
35. Ilan Y, Droguett G, Roy Chowdhury N, et al. Insertion of the Adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc Natl Acad Sci USA 1997;94:2587-92.
36. Ilan Y, Attavar P, Takahashi M, et al. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long-term gene therapy in Gunn rats. J Clin Invest 1996;98:2640-7.
37. Neurath MF, Fuss I, Pasparakis M, et al. Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur J Immunol 1997;27:1743-50.
38. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. Am J Pathol 1997;150:823-32.
39. Kuhn R, Lohler J, Rennick D. IL10 deficient mice develop chronic enterocolitis. Cell 1993;75:263-74.
40. Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to Interleukin 12 abrogate established experimental colitis in mice. J Exp Med 1995; 182:1281-90.
41. Marth T, Zeitz Z, Ludviksson B, et al. Murine model of oral tolerance. Induction of Fas-mediated apoptosis by blockade of interleukin-12. Ann NY Acad Sci 1998;17;859:290-4.
42. Hunter CA, Subauste CS, Van Cleave VH, et al. Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by Interleukin-10, Interleukin-12, and tumor necrosis factor alpha. Infect Immun 1994;62:2818-24.
43. Ogasawara K, Takeda K, Hashimoto W, et al. Involvement of NK1+ T cells and their IFN-gamma production in the generalized Shwartzman reaction. J Immunol 1998;160:3522-7.
44. Ma X, Chow JM, Cri G. The IL12 p40 gene promoter is primed by IFN in monocytic cells. J Exp Med 1996:183:147-157.
45. Arase H, Arase N, Saito T. IFN production by NK cells and NK1.1+T cells upon NKR-P1 cross-linking. J Exp Med 1996;183:2391-6.
46. Onoe Y, Harada M, Tamada K, et al. Involvement of both donor cytotoxic lymphocytes and host NK1.1+ T cells in the thymic atrophy of mice suffering from acute graft-versus-host disease. Immunology 1998;95:248-56.
47. Yoshimoto T, Paul WE. CD4posNK1.1 T cells promptly produce IL4 in response to in- vivo challenge with anti CD3. J Exp Med 1999;179:1285-95.
48. Zlotnik A, Godfrey DI, Fischer M. Cytokine production by mature and immature CD4+CD8-T cells produce IL4. J Immunol 1999;149:1121-1215.
49. Arase H, Arase-Fukushi N, Good RA, et al. Lymphokine-activated killer cell activity of CD4-CD8-TCR+ thymocytes J Immunol 1993;151:546-52.
50. Chen H, Paul WE. Cultured NK1.1+CD4+T cells produce large amounts of IL4 and IFNγ upon activation by anti CD3 or CD1. J Immunol 1997;159:2240-49.
51. Arase H, Arase N, Saito T. IFN production by NK cells and NK1.1+T cells upon NKR-P1 cross-linking. J Exp Med 1996;183:2391-6.
52. Arase H, Arase N, Nakagawa K. NK1.1+CD4+CD8- thymocytes with specific lymphokine secretion. Eur J Immunol 1999;23:307-10.
53. Seder RA, Gazzinelly R, Sher A, et al. IL12 acts directly on CD4+T cells to enhance priming for IFN production and diminishes IL4 inhibition of such priming. Proc Natl Acad Sci USA. 1999;90:10-188.
54. Trop S, Ilan Y. NK1.1+ T cell: a two-faced lymphocyte in immune modulation of the IL-4/IFN-gamma paradigm. J Clin Immunol 2002;22:270-80.
55. De-Moraes L, Moreau MC, Arnould G, et al. IL4 producing NK T cells are biased towards IFNγ production by IL12. Influence of the microenviroment on the functional capacities of NK T cells. Eur J Immunol 1998;28:1507-15.
56. Dobashi H, Seki S, Habu Y, et al. Activation of mouse liver natural killer cells and NK1.1+ T cells by bacterial superantigen-primed Kupffer cells. Hepatology 1999;30:430-6.
57. Tsukahara A, Seki S, Liai T, et al. Mouse liver T cells: Their change with aging and in comparison with peripheral T cells. Hepatology 1997;26:301-11.
58. Cui N, Watanabe T, Kawano C, et al. Inhibition of T helper cell type 2 cell differentiation and immunogolublin E response by Ligand activated vα14 Natural Killer T cells. J Exp Med 1999;190:783-92.
59. Kitamura H, Lwakabe K, Yahata T. The NK T cells ligand galactosylceramide demonstrates its immunopotentiating effect by inducing IL12 production by dendric cells and IL12 receptor expression on NKT cells. J Exp Med 1999;189:1121-7.
60. Fernandez NC, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in-vivo. Nat Med 1999;5:405-11.
61. Dao T, Mehal WZ, Crispe IN. IL18 augments perforin-dependent cytotoxicity of liver NKT cells. J Immunol 1998;161:2217-22.
62. Emoto M, Mittrucker HW, Schmits R, et al. Critical role of leukocyte function-associated antigen-1 in liver accumulation of CD4+ NKT cells. J Immunol 1999;162:5094-8.
63. Jonsson JR, Edwards-Smith CJ, Morotomi Y, et al. Expression of Fas/FasL and bcl2 in normal human liver derived leukocytes. Hepatology 1997;26:269A.
64. Stewart BH, Hoskin DW. The regulatory role of CD8 in major histocompatibility complex-unrestricted tumoricidal activity of mouse T cells activated with anti-CD3 monoclonal antibody. Immunol Invest 1997;26:601-14.
65. Kappeler A, Mueller C. The role of activated cytotoxic T cells in inflammatory bowel disease. Histol Histopathol 2000;15:167-72.